JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4136 TG101348 (SAR302503)
2 Citation

Target: FLT3|JAK|c-RET

Summary: JAK-2 inhibitor,potent and selective

≥26.23 mg/mL
A4147 LY2784544

Target: Aurora Kinases|FLT3|VEGFR|FGFR|Trk Receptors|JAK|ALK|TYK2|MUSK|MAP3K

Summary: JAK2 inhibitor,highly potent and selective

≥23.5 mg/mL
A4130 ENMD-2076

Target: Aurora Kinases|FLT3|RET|Src|VEGFR3/FLT4|NTRK1/TRKA|CSF-1R/c-Fms

Summary: Selective Aurora A/Flt3 inhibitor

insoluble in H2O; ≥18.75 mg/mL
A4123 KW 2449

Target: Aurora Kinases|FLT3|Bcr-Abl

Summary: Multikinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥16.6 mg/mL
A4124 TAK-901

Target: Aurora Kinases|FLT3|Src|JAK|LRRK2|Hck|FGR|YES|Fyn|ARG

Summary: Novel Aurora A/B inhibitor

≥25.25 mg/mL
A4125 CYC116

Target: Aurora Kinases|FLT3|VEGFR

Summary: Potent Aurora A/B inhibitor

insoluble in EtOH; insoluble in H2O; ≥18.4 mg/mL
A8889 G-749

Target: Aurora Kinases|FLT3|c-RET

Summary: FLT3 inhibitor

≥26.05 mg/mL
B8016 UNC2025
1 Citation

Target: MER|FLT3

Summary: orally bioavailable dual MER/FLT3 inhibitor

≥23.85 mg/mL
B5832 Altiratinib
1 Citation

Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2

Summary: c-MET/TIE-2/VEGFR inhibitor

≥21.55 mg/mL
B5835 AZD2932

Target: FLT3|VEGFR|PDGFR|c-Kit

Summary: inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit

Soluble in DMSO